Search Results for: "Clinic Roundup"
-
Clinic Roundup
PMDD is currently treated with antidepressants, but those treatments often are not effective or carry side effectsBioWorld Today | Friday, May 24, 2013 -
Clinic Roundup
clinical trials where a single dose of NX-1207 has been found to produce on average symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugsBioWorld Today | Monday, May 6, 2013 -
Clinic Roundup
One patient suffered serious adverse events that led to discontinuation, but all other side effects were mild and transientBioWorld Today | Tuesday, April 23, 2013 -
Clinic Roundup
GAL-021 was well tolerated with side effects similar to placeboBioWorld Today | Friday, April 12, 2013 -
Clinic Roundup
The company has found in studies to date that a single dose of NX-1207 produces symptomatic improvements about double those of currently approved BPH therapies without sexual or cardiovascular side effects...Common side effects of muscarinic antagonist therapies also were assessed in the 138 patients enrolled in the trial, with patients on the Tolenix arm showing statistically significant improvements in OAB and UUI symptoms over placeboBioWorld Today | Tuesday, March 19, 2013 -
Clinic Roundup
XmAb5871 is the first in a new class of therapeutic antibodies targeting the CD32b (FcγRIIb) pathway in B cells, which shows potential to suppress autoimmune disorders without the side effects caused by B-cell depletion, the company saidBioWorld Today | Thursday, February 14, 2013 -
Clinic Roundup
Infradure, a subcutaneous autologous skin tissue implant, is designed for the continuous production and delivery of interferon-alpha, to replace months of weekly injections and thereby reduce interferon side effectsBioWorld Today | Thursday, January 31, 2013 -
Clinic Roundup
No significant adverse events related to the drug occurred, and Nymox said NX-1207 treatment for BPH was not associated with the sexual, cardiovascular or other side effects associated with approved BPH medicationsBioWorld Today | Wednesday, January 23, 2013 -
Clinic Roundup
Patients receiving Tolenix, a twice-daily combination of muscarinic antagonist tolterodine and muscarinic agonist pilocarpine, exhibited no safety issues and also demonstrated statistically significant and clinically meaningful improvements in their saliva production and dry mouth side effects, as compared to DetrolBioWorld Today | Friday, January 4, 2013 -
Clinic Roundup
In the Phase I trial, 40 healthy volunteers who do not use methamphetamine received the medication over the past eight months and experienced no serious side effectsBioWorld Today | Tuesday, December 18, 2012 -
Clinic Roundup
Subjects had no significant side effects or complaintsBioWorld Today | Friday, November 16, 2012 -
Clinic Roundup
He also experienced no serious side effects from SL-401 treatmentBioWorld Today | Friday, November 9, 2012 -
Clinic Roundup
The product was well tolerated, with no serious side effects reported, and Aerie said it plans to advance into Phase IIb testingBioWorld Today | Friday, November 2, 2012 -
Clinic Roundup
DPX-Survivac was found to be safe and well tolerated, with no systemic side effects or dose-limiting toxicities to dateBioWorld Today | Thursday, October 11, 2012 -
Clinic Roundup
Consistent with the results previously reported for the study, PRX302 continued to be well tolerated with no erectile function side effects during the 12 months following treatmentBioWorld Today | Wednesday, October 10, 2012 -
Clinic Roundup
The highly potent ROCK inhibitor is based on Amakem's localized drug action platform, which generates novel kinase inhibitors that minimize the risk of systemic as well as local side effects, such as hyperemiaBioWorld Today | Friday, September 28, 2012 -
Clinic Roundup
Side effects were generally mild to moderate and, at the highest dose in some subjects, the improved lung ventilation was sufficient to increase in minute ventilation by more than 50 percent and in parallel lower CO2 levels more than 25 percentBioWorld Today | Friday, September 21, 2012 -
Clinic Roundup
The treatment regimen was well tolerated, with transient flu-like symptoms and transient leukopenia as the most common side effects related to JX-594BioWorld Today | Tuesday, September 18, 2012 -
Clinic Roundup
Tetraphase Pharmaceuticals Inc., of Watertown, Mass., reported Phase II data at the Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco, showing that eravacycline (TP-434) was highly active against drug-resistant bacterial pathogens, demonstrating infection cure rates similar to that of comparator ertapenem for the treatment of complicated intra-abdominal infections and a strong safety profile, with low rates of gastrointestinal side effectsBioWorld Today | Thursday, September 13, 2012 -
Clinic Roundup
Prior studies also showed that more than 90 percent of TC-5214 is eliminated unchanged through the bladder, supporting use of a low dose and creating the potential to minimize unwanted side effects. (See BioWorld Today, Nov. 9, 2011BioWorld Today | Thursday, September 6, 2012
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.